



Risks of ovarian, breast and corpus uteri cancer in women treated with assisted reproductive technology; 2.2 million person years of observation in Great Britain

Journal:	<i>BMJ</i>
Manuscript ID	BMJ.2018.043336
Article Type:	Research
BMJ Journal:	BMJ
Date Submitted by the Author:	18-Jan-2018
Complete List of Authors:	Williams, Carrie; UCL Great Ormond Street Institute of Child Health, Population Practice and Policy Jones, Michael; The Institute of Cancer Research, Aetiological Epidemiology Swerdlow, Anthony; Institute of Cancer Research, Department of Lifestyle and Participation Botting, Beverley ; UCL Great Ormond Street Institute of Child Health, Population Practice and Policy Davies, Melanie; University College London Hospitals NHS Foundation Trust, Reproductive Medicine Unit Jacobs, Ian; University of New South Wales, Bunch, Kathryn; National Perinatal Epidemiology Unit Murphy, Michael; University of Oxford Nuffield Department of Obstetrics and Gynaecology Sutcliffe, Alastair; UCL Great Ormond Street Institute of Child Health, Population Practice and Policy
Keywords:	In-vitro fertilisation, Breast Cancer, Ovarian Cancer, Corpus Uteri Cancer, Epidemiology, Assisted Reproduction, Data linkage

SCHOLARONE™
Manuscripts

1
2
3 **Title: Risks of ovarian, breast and corpus uteri cancer in women treated with assisted**
4 **reproductive technology; 2.2 million person years of observation in Great Britain**
5
6
7

8 **Authors' Names:** Carrie L Williams¹, Michael E Jones², Anthony J Swerdlow², Beverley J
9 Botting¹, Melanie C Davies³, Ian Jacobs^{3,4}, Kathryn J Bunch⁵, Michael FG Murphy⁶, and
10 Alastair G Sutcliffe¹.
11
12
13
14
15

16 **Addresses & Positions:** **1.** UCL Great Ormond Street Institute of Child Health, 30 Guilford
17 Street, London UK, WC1N 1EH (Carrie L Williams, NIHR Research Fellow; Beverley J Botting,
18 Reader; Alastair G Sutcliffe, Professor). **2.** The Institute of Cancer Research, 15 Cotswold
19 Road, Sutton, UK, SM2 5NG (Michael E Jones, Statistician; Anthony J Swerdlow, Professor). **3.**
20 The Institute for Women's Health, University College London Hospitals, 250 Euston Road,
21 London, NW1 2PG (Melanie C Davies, Consultant in Reproductive Medicine; Ian Jacobs,
22 Honorary Professor). **4.** University of New South Wales, Sydney, NSW, 2052, Australia, (Ian
23 Jacobs, Professor). **5.** The National Perinatal Epidemiology Unit, University of Oxford, Old
24 Road Campus, Oxford, UK, OX3 7LF (Kathryn J Bunch, Epidemiologist). **6.** Nuffield
25 Department of Obstetrics & Gynaecology, University of Oxford, Oxford UK (Michael FG
26 Murphy, Consultant Epidemiologist).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Correspondence to:** Professor Alastair Sutcliffe, Policy, Practice and Population Unit, UCL
45 Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street,
46 London, WC1N 1EH; a.sutcliffe@ucl.ac.uk; +442079052367.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The Corresponding Author has the right to grant on behalf of all authors and does grant on
4
5 behalf of all authors, a worldwide license to the Publishers and its licensees in perpetuity, in
6
7 all forms, formats and media (whether known now or created in the future) to i) publish,
8
9 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
10
11 other languages, create adaptations, reprints, include within collections and create
12
13 summaries, extracts and /or abstracts of the Contribution iii) create any other derivative
14
15 work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v)
16
17 the inclusion of electronic links from the Contribution to third party material where-ever it
18
19 may be located; and, vi) license any third party to do any or all of the above.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Objectives: Exposure to supra-physiological hormone levels and multiple ovarian punctures might increase cancer risks in women following assisted reproduction, however risks remain uncertain. This study aimed to investigate risks of corpus uteri, breast and ovarian cancer in women who have had assisted reproduction.

Design: Large population based data-linkage cohort study

Setting & Participants: All women who had assisted reproduction in Great Britain, 1991-2010, as recorded by the Human Fertilisation & Embryology Authority (HFEA).

Interventions: HFEA fertility records for cohort members were linked to national cancer registrations.

Main outcome measures: Observed first diagnosis of corpus uteri, breast or ovarian cancer in cohort members are presented in comparison with age, sex and period specific expectation. Standardized Incidence Ratios (SIRs) were calculated using age, sex and period-specific national incidence rates.

Results: 255,786 women contributed 2,257,789 person-years follow-up. No significant increased risk of corpus uteri cancer (164 cases observed compared to 146.9 cases expected; SIR 1.12; 95% Confidence Interval (CI) 0.95-1.30) was found during an average of 8.8 years follow-up. This study found no significant increased risks of breast cancer overall (2578 observed vs 2641.2 expected; SIR 0.98; 95%CI 0.94-1.01) or invasive breast cancer (2272 observed vs 2371.4 expected; SIR 0.96; 0.92-1.00). An increased risk of in-situ breast cancer (291 observed vs 253.55 expected; SIR 1.15; 1.02-1.29) was detected, associated with increasing number of treatment cycles ($P=0.03$). There was an increased risk of ovarian cancer (405 observed vs 291.8 expected; SIR 1.39; 1.26-1.53), both invasive (264 observed

1
2
3 vs. 188.1 expected SIR 1.40; 1.24-1.58) and borderline (141 observed vs.103.7 expected; SIR
4
5 1.36; 1.15-1.60). Increased risks of ovarian tumours were limited to women with
6
7 endometriosis, low parity, or both. This study found no increased risk of any ovarian tumour
8
9 in women treated because of only male factor or unexplained infertility.

10
11 **Conclusions:** No increased risk of corpus uteri or invasive breast cancer was detected, but
12
13 increased risks of in-situ breast cancer and invasive and borderline ovarian tumours were
14
15 found in this study. Our results suggest that ovarian tumour risks may be due to patient
16
17 characteristics, rather than assisted reproduction *per se*, although both surveillance bias and
18
19 the effect of treatment are also possibilities. Ongoing monitoring of this population is
20
21 essential.
22
23
24
25

26 **What this paper adds**

27
28 **What is already known on this subject:** Risks of reproductive cancers in women who have
29
30 undergone assisted reproduction procedures are uncertain. Some but not all previous
31
32 studies suggest possible increased risk of breast cancer in women treated at younger ages
33
34 and with multiple cycles. Previous studies investigating endometrial cancer risk are
35
36 underpowered. Early studies suggested increased risks of ovarian cancer in these women,
37
38 whilst more recent studies are more reassuring, although inconsistent regarding any
39
40 increase in borderline ovarian tumours.
41
42
43
44

45 **What this study adds:** This population-based study is the largest such study to date.
46
47 Endometrial cancer was not increased in women who have had assisted reproduction when
48
49 compared to the general population. There was no increased risk of breast cancer overall,
50
51 nor invasive breast cancer, but a small increase in in-situ breast cancer. Increased risks of
52
53 ovarian cancer, both invasive and borderline, were observed but limited to women with
54
55 other known risk factors. These findings require further investigation.
56
57
58
59
60

INTRODUCTION:

Assisted reproduction cycles usually involve exposure to supra-physiological levels of oestradiol, exogenous gonadotropins and multiple ovarian punctures, all potentially carcinogenic^{1,2}. Most concern surrounds risks of breast, endometrial and ovarian cancers after such exposures³⁻¹⁷.

Studies investigating breast cancer risks in women who underwent assisted reproduction are inconsistent⁴⁻¹³. Some suggest possible increased risk within subgroups^{9,10}, including women treated at younger ages¹⁰ and with multiple cycles⁹. Most studies investigating endometrial cancer risk have shown a small or borderline increase but include few events^{4,5,7}. Early studies investigating fertility drugs used alone suggested increased risks of ovarian cancer³. Recent investigations into their use as part of assisted reproduction have generally been more reassuring, but remain inconsistent and at risk of bias^{5,6,12}. Some^{14,15}, but not all studies⁷ have found an increase in borderline tumours.

Given previous inconsistent results, small study size, and lack of information on potential confounders, we undertook a population-based linkage study in Britain to provide risk estimates for breast, corpus uteri and ovarian cancer, in a cohort of over 266,000 women undergoing assisted reproduction, with information on potential confounders such as parity and infertility diagnosis.

METHODS:**STUDY POPULATION**

We defined assisted reproduction as 'treatments or procedures that include in vitro handling of both human oocytes and sperm or embryos, for the purpose of establishing

1
2
3 pregnancy¹⁸. Records for all women undergoing assisted reproduction, January 1991 to
4
5 September 2009, and those undergoing the same, October 2009 to December 2010 who
6
7 gave their prospective consent, in England, Wales and Scotland were obtained from the
8
9 Human Fertilisation and Embryology Authority (HFEA).

10
11
12
13
14 UK law mandates reporting of all assisted reproduction cycles to the HFEA. For cycles
15
16 performed before October 2009, research use of these data was permitted, but consent
17
18 could be withdrawn retrospectively. 0.3% of the cohort had done so before this study began.
19
20 The study cohort, January 1991 to September 2009, therefore represents 99.7% of the at-
21
22 risk population. For cycles performed October 2009 onwards, prospective consent was
23
24 required. Overall 7% of women undergoing assisted reproduction, 1991-2010, were not
25
26 included in this study, representing a loss of less than 1% of person-years follow-up
27
28 (*Supplementary appendix*).

31 32 33 34 35 PATIENT INVOLVEMENT & STUDY APPROVAL

36
37 Representatives from patient support groups (Fertility Network UK) were consulted on the
38
39 original research question, design and planning of this study. Approval of the study and
40
41 waiver of the requirement for individual consent were obtained from the UK Health
42
43 Research Authority Confidentiality Advisory Group and London Research Ethics Committee
44
45 (References 5.04(b)/10 & 10/H0720/18 respectively). Given the anonymous nature of the
46
47 final dataset, it is not possible to disseminate results to individual study participants; instead
48
49 results will be shared with fertility practitioners and clinics through the Human Fertility &
50
51 Embryology Authority networks.
52
53
54
55
56
57
58
59
60

OUTCOME DATA

HFEA records were linked to the National Health Service Central Registers of England, Wales, and Scotland (from which emigrations, deaths and cancer registrations are reported to authorised medical researchers) in a one-off linkage. Completeness and accuracy of these registers have been described¹⁹⁻²¹. Overall, records of 266,787 eligible women (95.1%) were linked (*Supplementary appendix*). Cancer diagnosis date, topography code (ICD9/ICD10), morphology (ICD-O-2/ICD-O-3), and behaviour (ICD-O-2/ICD-O-3), were available where an incident cancer was diagnosed. Women with cancer diagnoses recorded prior to first treatment year were excluded from analyses. Data relating to potential confounding factors such as infertility diagnosis, parity (as recorded at last treatment cycle completion) and to treatment details including number of stimulated cycles and age at first treatment were obtained for each cohort member from the HFEA database. These data are a combination of patient self-reported and clinic reported (*Table S1 Supplementary appendix*). Information regarding infertility diagnoses are reported to the HFEA by assisted reproduction clinics, based on investigations undertaken by that clinic, the referring clinician or rarely patient self-report.

STATISTICAL ANALYSES

Person-years at risk were calculated from date of first treatment (estimated as mid-point of first treatment year), until date of any cancer diagnosis, death, emigration or study end (March 2011), whichever came first. For analyses involving number of cycles, infertility duration, live and multiple births, person-years at risk were calculated from date of last treatment (estimated as mid-point of last treatment year), as the HFEA did not record intermediate dates required for time dependent analysis. Expected cancers were calculated

1
2
3 multiplying person-years at risk by corresponding national incidence rates (by 5-year age
4
5 band and individual calendar year) for the general female population of England & Wales.
6
7 Standardized incidence ratios (SIR) were calculated comparing observed to expected values.
8
9
10 95% confidence intervals, 2-sided *P*-values and trends were calculated assuming a Poisson
11
12 distribution²². Sensitivity analyses excluded the first 12 months of follow-up (*Supplementary*
13
14 *appendix*). Analyses were performed using STATA, version 12²³.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS:

CHARACTERISTICS OF STUDY PARTICIPANTS:

255,786 women contributed 2,257,789 person-years follow-up. Average follow-up was 8.8 years with 41% followed for ≥ 10 years. Average age at first treatment was 34.5 years. Infertility cause involved at least one female factor in 44% (including endometriosis; ovulatory disorders- predominantly polycystic ovary disease; and tubal disease). Infertility was unexplained in 19% of women and due only to male factor in 33%. Average infertility duration was 4.9 years. Women had 1.8 stimulated cycles on average, only 20% having > 2 stimulated cycles. Approximately half had at least one live birth after treatment completion (*Table 1*).

BREAST CANCER

There was no overall increased risk of breast cancer (2578 observed vs. 2641.2 expected cancers; SIR 0.98; 95%CI 0.94-1.01; *Table 2*). 76% of tumours were ductal carcinomas (n=1,963), 9% lobular (n=228), 12% other epithelial tumours (n=319), and 3% non-epithelial or unspecified (n=68). There were also no significant raised risks in strata by age at first treatment, infertility duration, number of stimulated cycles, number of live births and multiple births. There were significant risk reductions with increasing duration since treatment completion ($P=0.01$; *Table 3*), and in women with any female factor or only male factor infertility (*Table 3*), but no difference between risks at pre and post-menopausal ages separately (age: < 50 years, SIR=0.98; 0.94-1.02; ≥ 50 years, SIR=0.97; 0.89-1.06; *data not shown*). Excluding the first 12 months follow-up, breast cancer risk was significantly reduced compared with age-standardized expectation (SIR 0.95; 0.92-0.99, $P=0.02$; *Supplementary*

1
2
3 *appendix*). There was no increased risk of invasive breast cancer (SIR 0.96; 0.92-1.00; *Table*
4
5 4) but an increased risk of in-situ breast cancer (SIR 1.15; 1.02-1.29; *Table 4*), which was
6
7 associated with number of treatment cycles ($P=0.03$). Excluding the first 12 months follow-
8
9 up did not substantially change results for in-situ breast cancer risk (*Supplementary*
10
11 *appendix*).

12 13 14 15 CARCINOMA OF THE CORPUS UTERI

16
17
18 Corpus uteri cancer risk was not significantly raised (SIR 1.12; 0.95-1.30; *Table 2*). Over 92%
19
20 (n=152) of corpus uteri tumours were epithelial, 70% (n=107) of which were endometrioid.
21
22 8% were non-epithelial or unspecified (n=12). Significantly increased risk was observed in
23
24 women with an ovulatory disorder (SIR 1.59; 1.13-2.17; *Table 3*). There was a highly
25
26 significant trend of increasing risk with decreased parity ($P<0.001$) and having a multiple
27
28 birth significantly decreased risk (SIR 0.42; 0.14-0.99; *Table 3*). No significant variation in risk
29
30 was noted with number of cycles ($P=0.93$), age at first treatment ($P=0.28$) or duration since
31
32 treatment completion ($P=0.12$). Excluding the first 12 months follow-up did not substantially
33
34 change results (*Supplementary appendix*).

35 36 37 38 39 OVARIAN CANCER

40
41
42 An overall increased risk of ovarian cancer was observed (SIR 1.39; 1.26-1.53; *Table 2*).
43
44 Increased risks were seen across most age groups at first treatment, but there was a highly
45
46 significant trend of increasing risk with decreasing age at first treatment ($P<0.001$; *Table 3*).
47
48 Significantly increased risks were found in women who had any diagnosis of female factor
49
50 infertility (SIR 1.66; 1.46-1.88; *Table 3*), particularly endometriosis (SIR 2.31; 1.74-3.01; *Table*
51
52 3) or tubal disease (SIR 1.68; 1.43-1.97; *Table 3*). No increased risk was seen where infertility
53
54
55
56
57
58
59
60

1
2
3 was male factor only (SIR 1.05; 0.85-1.27) or unexplained (SIR 0.96; 0.69-1.31; *Table 3*).

4
5 There was a significant trend of decreasing risk with increasing number of live births
6
7 ($P=0.001$; *Table 3*): remaining nulliparous after treatment completion conferred highest risk

8
9 (SIR 1.57; 1.37-1.79; *Table 3*). No increased risk was seen with increasing infertility duration
10
11 ($P=0.15$), number of cycles ($P=0.86$) or duration since treatment completion ($P=0.74$).

12
13 Excluding the first 12 months follow-up did not substantially change results (*Supplementary*
14
15 *appendix*).

16
17
18
19 When tumours were classified as invasive or borderline, significant excesses of both (SIR
20
21 1.40; 1.24-1.58; and SIR 1.36; 1.15-1.60 respectively; *Table 4*) were noted.

22 23 24 25 INVASIVE OVARIAN TUMORS

26
27
28 There was a significant trend of increasing risk of invasive ovarian tumours with decreasing
29
30 age at first treatment ($P=0.02$; *Table 4*). Significantly increased risks were detected in

31
32 women who had any diagnosis of female factor infertility (SIR 1.66; 1.41-1.94; *Table 4*),

33
34 particularly endometriosis (SIR 2.47; 1.75-3.39; *Table 4*) or tubal disease (SIR 1.71; 1.40-2.08;

35
36 *Table 4*). Risk significantly decreased with increasing parity ($P=0.001$): women nulliparous

37
38 after treatment completion were at greatest risk (SIR 1.67, 1.42-1.95; *Table 4*). There was no

39
40 significant variation in risk with number of cycles ($P=0.29$), infertility duration ($P=0.25$) or

41
42 duration since treatment completion ($P=0.44$). 33% of invasive ovarian tumours were serous

43
44 (n=87), 25% endometrioid (n=66), 8% mucinous (n=22), 18% other or unspecified epithelial

45
46 tumours (n=45), and 17% non-epithelial or unspecified (n=44). Excluding the first 12 months

47
48 follow-up did not substantially change results.

49 50 51 52 53 54 BORDERLINE OVARIAN TUMORS

1
2
3 Significantly increased risks of borderline ovarian tumour was associated with decreasing
4
5 age at first treatment ($P<0.001$; *Table 4*) and any diagnosis of female factor infertility (SIR
6
7 1.66; 1.33-2.05; *Table 4*), particularly endometriosis (SIR 2.03; 1.18-3.25; *Table 4*), or tubal
8
9 disease (SIR 1.62; 1.21-2.12; *Table 4*). Risk did not change significantly with number of cycles
10
11 ($P=0.18$), parity ($P=0.34$), infertility duration ($P=0.42$), or duration since treatment
12
13 completion ($P=0.84$). 45% of borderline tumours were serous ($n=64$), 34% mucinous ($n=48$),
14
15 <2% endometrioid ($n<5$), <2% other or unspecified epithelial tumours ($n<5$), and 18% non-
16
17 epithelial or unspecified ($n=25$). Excluding the first 12 months follow-up reduced the risk of
18
19 borderline ovarian tumour (SIR 1.19; 0.98-1.43; *Supplementary appendix*) and risk in relation
20
21 to endometriosis (SIR 1.57; 0.81-2.73; *Supplementary appendix*).
22
23
24
25

26 OVARIAN CANCER RISK STRATIFIED BY RISK FACTORS

27
28
29 Parous women who did not have a diagnosis of endometriosis did not have an increased risk
30
31 of ovarian cancer overall (SIR 1.03; 0.86-1.22; *Table 5*), invasive (SIR 1.03; 0.82-1.27; *Table*
32
33 *5*), or borderline tumours (SIR 1.02; 0.75-1.35; *Table 5*). Risks of all types of ovarian cancer
34
35 were raised in nulliparous women who did not have a diagnosis of endometriosis but to a
36
37 lesser extent than in parous women with endometriosis (*Table 5*). Women who were
38
39 nulliparous with a diagnosis of endometriosis had greater risk of invasive ovarian tumour
40
41 (SIR 2.64; 1.69-3.93; *Table 5*) than women with just one of these risk factors. In contrast,
42
43 nulliparous women with endometriosis had no significant risk of a borderline tumour (SIR
44
45 1.47; 0.59-3.04; *Table 5*), though nulliparity and endometriosis were each separately
46
47 associated with increased risk (*Table 5*). The significant association between decreasing age
48
49 at first treatment and increasing risk of invasive ovarian tumour was present in women with
50
51
52
53
54
55
56
57
58
59
60

1
2
3 at least one of endometriosis or nulliparity ($P<0.001$), but not in those without either
4
5 ($P=0.62$); however these analyses were based on small numbers (*Supplementary appendix*).
6
7

8 **DISCUSSION:**

9
10 Assisted reproduction is practiced worldwide and more than 5 million children have been
11
12 born as a result²⁴. It is important to establish related disease risks for affected individuals,
13
14 public health systems, and for counselling of potential patients. In this large population-
15
16 based cohort, we found no overall increased risk of breast cancer, consistent with most⁴⁻
17
18 ^{8,10,11} but not all¹³ published studies. We found no significant association between risk of
19
20 breast cancer and age at first treatment, in contrast to a small number of earlier
21
22 studies^{9,10,25}. Reasons for significant decreases in breast cancer risk seen in some sub-
23
24 analyses, such as women who had assisted reproduction for female factor infertility, are
25
26 unclear. These may reflect beneficial levels of lifestyle-related risk factors for breast
27
28 cancer^{26,27}. Unfortunately, details of these risk factors and also age at first birth were not
29
30 available. Menopausal status did not seem to account for the significant reduction in risk
31
32 with increasing follow-up. There was no increased risk of invasive breast tumours. However
33
34 there was a significant increase in in-situ tumours; significantly associated with increasing
35
36 number of stimulated cycles. Interpretation of these findings is challenging: the significant
37
38 association with increasing number of cycles is suggestive of an aetiological relationship, yet
39
40 there was no overall increased risk of breast cancer. Other potential explanations include
41
42 surveillance bias, chance and potential confounding by factors such as socio-economic
43
44 status, given that most cycles within our cohort were privately funded. To our knowledge
45
46 this study is the first to analyse risks of in-situ and invasive breast cancers after assisted
47
48 reproduction separately, so there are no previous data with which to compare.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Overall corpus uteri cancer risk was not raised. Women with the known risk factor of
4 nulliparity²⁸ and those with a history of ovulatory problems (mainly the known risk factor
5 polycystic ovary disease²⁹) were found to have an increased risk. Most similar studies
6 contained few events^{4,6,7}. The largest included 15⁵ and 49 cases⁸, neither suggested an
7 increased risk.
8
9

10
11 We found an excess of ovarian cancer compared with age-standardized expectation.
12
13 Significant increases were observed for both invasive and borderline tumours, but were not
14 seen in women without the known risk factors of endometriosis^{30,31} and nulliparity³¹.
15
16 Ovarian cancer risks were not associated with number of treatment cycles, time since
17 treatment completion or male factor or unexplained infertility, which argues against a causal
18 role for assisted reproduction procedures *per se*. However, we did find a significant
19 association between age at first treatment and all ovarian cancer, invasive, and borderline
20 tumour risk. Previous studies investigating invasive ovarian tumour risk after assisted
21 reproduction^{4-8,12,14,16,17} have generally found increased risks in comparison with the general
22 population when potential confounding effects of infertility have not been considered¹⁷, but
23 not when such factors were taken into account^{4,5,12,17}. Whilst our study compared cancer
24 incidence with that in the general population (standardized for age and calendar year), it has
25 sufficient size to stratify by potential confounding factors and thereby investigate
26 characteristics of associations. We found an increased risk of borderline ovarian tumour in
27 women having assisted reproduction compared with the general population. As with
28 invasive ovarian tumours, this increased risk was not seen in parous women without
29 endometriosis. Few studies have investigated the risk of borderline ovarian cancer in women
30 after assisted reproduction^{7,14,15}, but increased risks have been found in smaller studies in
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the Netherlands¹⁴ and Australia¹⁵. While the increased risk could be genuine, it could also be
4
5 due to surveillance bias. The frequency of borderline tumour diagnosis is increased in
6
7 ovarian cancer screening studies using ultrasound³² and women who have undergone
8
9 assisted reproduction might have more frequent ultrasound scans post treatment than the
10
11 general population. This is supported by the reduction in overall risk excluding the first 12
12
13 months follow-up. However, sensitivity analyses looking at time to diagnosis, age at
14
15 diagnosis, diagnosis in women of high socio-economic status and clinical presentation in
16
17 other studies suggested surveillance bias an unlikely cause of increased risks^{14,15}. We are not
18
19 able to further differentiate surveillance bias from a genuine increase in borderline tumours.
20
21 Women with unrecorded cause of infertility had significantly increased rates of breast,
22
23 ovarian and corpus uteri cancers. Reasons are unclear but might include reverse causality
24
25
26
27
28 (*supplementary appendix*).
29
30

31 **Strengths and Limitations**

32
33
34 Most studies investigating risks of cancer in women after assisted reproduction have been
35
36 small^{7,9}, with few events and short follow-up⁵⁻⁸. The two largest published to date include
37
38 67,608⁵ and 113,226⁸ women treated with assisted reproduction. Systematic reviews have
39
40 included at most 70,753 treated women for analyses of breast cancer risk¹¹ and 79,143 for
41
42 ovarian cancer¹⁷. Our study comprised over 250,000 treated women. We included almost
43
44 65,000 person-years follow up for ≥ 15 years beyond last treatment with an average follow
45
46 up of 8.8 years and a maximum follow-up of 19 years (*Table S2 supplementary appendix*),
47
48 but cannot exclude the possibility of different risk profiles for any studied cancer on longer
49
50 follow-up, at ages when most reproductive-related cancers occur³¹. Women treated with
51
52 assisted reproduction are likely to differ from the general population in their parity, age at
53
54
55
56
57
58
59
60

1
2
3 first birth, age at menopause, and the incidence of pre-disposing conditions, such as
4
5 endometriosis. More information on these and others factors, such as socio-economic
6
7 status, oral contraceptive use, body mass index, and breast-feeding would be useful.
8
9
10 Comparison to women who have untreated infertility problems may have been beneficial,
11
12 although interpretational problems would remain because of potential selection factors for
13
14 treatment. Whilst our study was not able to compare with such a group as some smaller
15
16 studies have done^{5,14,15}, large study size enabled us to stratify for some important potential
17
18 confounders and draw inferences despite using general population rates as our comparator.
19
20
21 Whilst comparator rates do include cohort participants, <5% of the population of
22
23 reproductive-age women underwent assisted reproduction and our SIRs were generally
24
25 <2.0; therefore resulting bias will have been minimal³³. Further details of specific
26
27 treatments may have enabled detailed analysis of risk by treatment type. However over our
28
29 19 year study period, ovarian stimulation regimens as part of assisted reproductive cycles
30
31 have been relatively constant, the majority of advances leading to better success rates
32
33 having occurred in assisted reproduction laboratories. Gonadotropin injections have been
34
35 used for ovarian stimulation and human chorionic gonadotropin for triggering ovulation
36
37 throughout the study period, and whilst new highly purified and recombinant versions have
38
39 been used in more recent years, they are essentially equivalent. Clomiphene citrate was
40
41 used as additional ovarian stimulation in the pioneering years of assisted reproduction
42
43 treatment, but this was uncommon by 1991. Down-regulated cycles using GnRH-agonists
44
45 were standard by 1991 and not replaced by GnRH antagonists as standard until after the
46
47 study period. Progesterone support was used throughout the study period. The number of
48
49 ovarian punctures per cycle and information about fertility treatment prior to assisted
50
51 reproduction were not available.
52
53
54
55
56
57
58
59
60

Conclusions and Implications

In this large, national population-based study of British women after assisted reproductive technology treatment, no increased risk of corpus uteri or invasive breast cancer was detected. There was an increased risk of in-situ breast cancer associated with increasing number of treatment cycles. We also observed an excess of all types of ovarian cancer. However, our results suggest this is more likely due to underlying patient characteristics, rather than assisted reproduction *per se*. We were not able to distinguish between a genuine increase in borderline ovarian tumour risk and other explanations including surveillance bias. Further investigation of this and longer follow-up is warranted to continue monitoring these important outcomes in this ever-growing population.

1
2
3 **Acknowledgements and funding:** *This research was funded by Cancer Research UK (11704)*
4 *and the National Institute for Health Research (405526 to Dr Williams) and supported by the*
5 *National Institute for Health Research Biomedical Research Centre at Great Ormond Street*
6 *Hospital for Children NHS Foundation Trust and University College London. Dr Jones is funded*
7 *by Breast Cancer Now. The Institute of Cancer Research acknowledges NHS funding to the*
8 *Royal Marsden/ICR NIHR Biomedical Research Centre. No funders or sponsors had any role in*
9 *the study design, data collection, analysis, interpretation of data and decision to submit for*
10 *publication. All researchers are independent from funders and sponsors.*

11
12
13
14
15
16
17
18
19
20
21
22 **Contributions & Guarantor:** *We thank the Human Fertilisation and Embryology Authority for*
23 *access to their original dataset and advice on data governance. We thank the National*
24 *Health Service Digital and National Records for Scotland for their roles in the data linkage*
25 *process and access to cancer registration data.*

26
27
28
29
30
31
32
33 *Dr Carrie Williams jointly conceptualized and designed the study, devised the linkage*
34 *protocol, supervised the linkage, carried out the analysis, interpreted data, drafted the initial*
35 *manuscript and approved the final manuscript as submitted. Dr Michael Jones jointly*
36 *conceptualized and designed the study, jointly supervised the analysis, interpreted data,*
37 *reviewed and revised the manuscript, and approved the final manuscript as submitted.*
38 *Professor Anthony Swerdlow jointly conceptualized and designed the study, interpreted data,*
39 *reviewed and revised the manuscript, and approved the final manuscript as submitted. Dr*
40 *Beverley Botting jointly conceptualized and designed the study, jointly supervised the*
41 *analysis, interpreted data, reviewed and revised the manuscript, and approved the final*
42 *manuscript as submitted. Dr Melanie Davies jointly conceptualized and designed the study,*
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *interpreted data, reviewed and revised the manuscript, and approved the final manuscript as*
4 *submitted. Professor Ian Jacobs jointly conceptualized and designed the study, interpreted*
5 *data, reviewed and revised the manuscript, and approved the final manuscript as submitted.*
6
7
8
9
10 *Mrs Kathryn Bunch jointly conceptualized and designed the study, interpreted data, reviewed*
11 *and revised the manuscript, and approved the final manuscript as submitted. Dr Michael*
12 *Murphy jointly conceptualized and designed the study, interpreted data, reviewed and*
13 *revised the manuscript, and approved the final manuscript as submitted. Professor Alastair*
14 *Sutcliffe jointly conceptualized and designed the study, interpreted data, reviewed and*
15 *revised the manuscript, and had the final decision over submission of the approved the final*
16 *manuscript. All authors had access to the data and take responsibility for the integrity of the*
17 *data and accuracy of the data analysis.*
18
19
20
21
22
23
24
25
26

27
28
29
30 *Professor Sutcliffe acts as guarantor for this study.*
31
32
33
34

35 **Transparency Declaration:** Professor Sutcliffe affirms that the manuscript in an honest,
36 accurate and transparent account of the study. No important aspects of the study have been
37 omitted and any discrepancies from the study as planned have been explained.
38
39
40
41
42
43

44 **Data Sharing Statement:** No additional data are available, in compliance with ethical and
45 governance regulations under which this research was undertaken.
46
47
48
49
50

51 **Competing Interests:** All Authors have completed the ICMJE uniform disclosure form and
52 declare funding for this study from Cancer Research UK and National Institute for Health
53 Research. MJ additionally received funding from Breast Cancer Now. KB and MM received
54
55
56
57
58
59
60

1
2
3 funding from the UK Department of Health, Children with Cancer UK, during the study. IJ
4
5 reports personal fees from Abcodia Ltd & Women's Health Specialists. IJ receives royalties as
6
7 co-inventor of ROCA algorithm. MD reports personal fees from the Centre for Reproductive
8
9 and Genetic Health. The authors declare no other relationships or activities that could
10
11 appear to have influenced the submitted work.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Table 1: Characteristics of 225,786 women who underwent assisted reproduction in Great Britain, 1991–2010

Characteristic	Total N=255, 786	Women who developed a cancer of the breast, ovary or corpus uteri N=3,155	Women who did not develop a cancer of the breast, ovary or corpus uteri N= 252,631
Mean age at first treatment- years (+/- Standard Deviation (SD))	34.5 +/- 4.8	36.3 +/- 4.7	34.5 +/- 4.8
Age at first treatment (years), No. (%)			
< 25	5,671 (2)	20 (1)	5,651 (2)
25-29	39,932 (16)	259 (8)	39,673 (16)
30- 34	92,788 (36)	961 (31)	91,827 (36)
35- 39	85,868 (34)	1,244 (39)	84,624 (34)
40-44	28,174 (11)	563 (18)	27,611 (11)
45+	3,353 (1)	108 (3)	3,245 (1)
Cause of infertility, No. (%)			
Any female factor	111,658 (44)	1,626 (52)	110,032 (44)
Male factor only	84,871 (33)	915 (29)	83,956 (33)
Unexplained	47,757 (19)	474 (15)	47,283 (19)
Unrecorded	11,500 (5)	140 (4)	11,360 (5)
History of endometriosis, No. (%)	18,630 (7)	281 (9)	18,349 (7)
History of tubal disease No. (%)	66,370 (26)	1045 (33)	65,325 (26)
History of ovulatory disorder, No. (%)	36,016 (14)	451 (14)	35,565 (14)
Mean duration of infertility reported at completion of last cycle Years +/- SD	4.9 +/- 3.3	5.6 +/- 3.9	4.8 +/- 3.3
Average number of stimulated cycles	1.8 +/-1.2	1.8 +/- 1.3	1.8 +/- 1.2
Average number of live births at completion of last cycle	0.6 +/- 0.7	0.6 +/- 0.7	0.6 +/- 0.7
Number of live births at completion of last cycle, No. (%)			
0	129,217 (51)	1,775 (56)	127,442 (50)
1	96,839 (38)	1,011 (32)	95,828 (38)
2+	29,645 (12)	368 (12)	29,277 (11)
Unrecorded	85 (0)	1 (0)	84 (0)
Any multiple birth recorded at completion of last cycle, No. (%)	29,366 (11)	304 (10)	29,062 (12)

Table 2: Relative and absolute excess risks of cancers of breast, ovary, and corpus uteri among 225,786 women who underwent assisted reproduction in Great Britain, 1991–2010, including and excluding the first year after the start of treatment.

Type of cancer	Person years follow-up	Observed cancers	Expected cancers	Standardized Incidence Ratio (95%CI)	AER [†] (95% CI)
Including the first year of follow-up					
Breast [‡]	2257789	2578	2641.2	0.98 (0.94-1.01)	-2.8 (-7.1 - 1.8)
Corpus uteri [§]	2257789	164	146.9	1.12 (0.95-1.30)	0.8 (-0.3 - 2.0)
Ovary	2257789	405	291.82	1.39 (1.26-1.53)***	5.0 (3.3 – 6.9)
Excluding the first year of follow-up					
Breast [‡]	2004121	2384	2501.6	0.95 (0.92-0.99)*	-5.9 (-10.6 - -1.0)
Corpus uteri [§]	2004121	157	141.79	1.11 (0.94-1.30)	0.8 (-0.4 - 2.1)
Ovary	2004121	356	271.9	1.31 (1.18-1.45)***	4.2 (10.5 – 9.3)

Table 3. Standardized incidence ratios for breast, ovarian and corpus uteri cancer among 225,786 women who underwent assisted reproduction in Great Britain, 1991–2010 stratified by various factors.

Factor	Type of Cancer [¶]					
	Breast [‡]		Corpus Uteri [§]		Ovarian	
	Observed cancers	SIR (95%CI)	Observed Cancers	SIR (95%CI)	Observed cancers	SIR (95%CI)
Age at first treatment (years)						
<25	14	1.32 (0.72-2.21)	0	0.00 (0.00-6.97)	6	2.21 (0.81-4.80)
25-29	185	0.92 (0.79-1.06)	10	1.24 (0.60-2.29)	64	2.16 (1.67-2.76)***
30-34	774	0.95 (0.89-1.02)	43	1.19 (0.86-1.60)	142	1.52 (1.28-1.80)***
35-39	1033	0.97 (0.91-1.03)	72	1.22 (0.96-1.54)	134	1.23 (1.03-1.45)*
40-44	479	1.02 (0.93-1.12)	33	0.96 (0.66-1.35)	50	1.05 (0.78-1.38)
45+	93	1.09 (0.89-1.34)	6	0.68 (0.25-1.48)	9	0.97 (0.45-1.85)
	Trend across categories P=0.13		Trend across categories P=0.28		Trend across categories P<0.001	
Infertility cause						
Any female factor	1279	0.95 (0.90-1.00)*	97	1.25 (1.02-1.53)*	246	1.66 (1.46-1.88)***
Male factor only	774	0.92 (0.86-0.99)*	41	0.91 (0.65-1.24)	98	1.05 (0.85-1.27)
Unexplained	416	1.10 (1.00-1.21)	16	0.78 (0.45-1.27)	40	0.96 (0.69-1.31)
Unrecorded	109	1.49 (1.24-1.80)***	10	2.53 (1.21-4.66)*	21	2.59 (1.60-3.95)**
History of endometriosis						
Yes	214	0.98 (0.86-1.12)	9	0.75 (0.35-1.43)	55	2.31 (1.74-3.01)***
No	2364	0.98 (0.94-1.02)	155	1.15 (0.98-1.34)	350	1.31 (1.17-1.45)***
History of tubal disease						
Yes	826	0.96 (0.90-1.03)	59	1.23 (0.93-1.58)	158	1.68 (1.43-1.97)***
No	1752	0.98 (0.94-1.03)	105	1.06 (0.87-1.29)	247	1.25 (1.10-1.41)***
History ovulatory problems						
Yes	357	0.92 (0.83-1.02)	39	1.59 (1.13-2.17)**	55	1.28 (0.97-1.67)
No	2221	0.99 (0.95-1.03)	125	1.02 (0.85-1.21)	350	1.41 (1.26-1.56)***

Duration of infertility at last cycle (years)						
< 2	171	0.95 (0.82-1.11)	6	0.55 (0.20-1.20)	28	1.44 (0.96-2.09)
2-3	527	1.05 (0.96-1.14)	23	0.82 (0.52-1.23)	73	1.30 (1.02-1.64)*
4-5	520	0.99 (0.90-1.07)	30	1.03 (0.70-1.47)	74	1.27 (1.00-1.60)
6-7	316	0.91 (0.82-1.02)	27	1.38 (0.91-2.01)	60	1.61 (1.23-2.07)**
8-9	197	0.95 (0.83-1.10)	16	1.34 (0.77-2.18)	36	1.64 (1.15-2.27)**
10+	322	0.95 (0.85-1.05)	37	1.68 (1.18-2.31)**	57	1.60 (1.21-2.08)**
Unrecorded	404	1.07 (0.97-1.18)	18	0.92 (0.54-1.45)	42	1.02 (0.74-1.38)
	Trend across categories P=0.20		Trend across categories P<0.001		Trend across categories P=0.15	
Total number of stimulated cycles						
0 – 'natural cycle' only	142	0.88 (0.74-1.04)	8	0.66 (0.28-1.29)	17	0.99 (0.58-1.59)
1	1203	0.98 (0.92-1.03)	89	1.29 (1.04-1.59)*	196	1.44 (1.25-1.66)***
2	585	1.01 (0.93-1.09)	29	0.91 (0.61-1.30)	87	1.38 (1.10-1.70)**
3-4	420	1.03 (0.93-1.13)	24	1.06 (0.68-1.58)	53	1.23 (0.92-1.60)
5+	107	1.08 (0.89-1.31)	7	1.24 (0.50-2.55)	17	1.67 (0.97-2.67)
Unrecorded	0	0 (0.00-29.96)	0	0.00 (0.00-13.03)	0	0.00 (0.00-299.57)
	Trend across categories P=0.07		Trend across categories P=0.93		Trend across categories P=0.86	
Total number of live births at last cycle completion						
0	1299	0.99 (0.93-1.04)	122	1.61 (1.34-1.92)***	222	1.57 (1.37-1.79)***
1	843	1.03 (0.96-1.10)	24	0.53 (0.34-0.79)***	114	1.25 (1.03-1.50)*
2+	314	0.92 (0.82-1.03)	11	0.54 (0.27-0.96)*	34	0.93 (0.64-1.30)
Unrecorded	1	1.82 (0.05-10.13)	0	0.00 (0.00-99.86)	0	0.00 (0.00-49.93)
	Trend across categories P=0.56		Trend across categories P<0.001		Trend across categories P=0.001	
Any multiple birth as recorded at last cycle completion						
Yes	258	1.10 (0.97-1.24)	5	0.42 (0.14-0.99)*	33	1.23 (0.85-1.73)
No	2199	0.98 (0.94-1.02)	152	1.17 (1.00-1.38)	337	1.39 (1.24-1.54)***

Time since last treatment (years)						
0-3	525	1.04 (0.95-1.13)	28	1.39 (0.92-2.00)	99	1.54 (1.25-1.88)***
3-6	529	1.04 (0.95-1.13)	29	1.28 (0.85-1.83)	73	1.27 (1.00-1.60)
6-10	657	1.00 (0.93-1.08)	38	1.07 (0.76-1.47)	84	1.24 (0.99-1.53)
10-15	590	0.93 (0.86-1.01)	45	0.99 (0.72-1.33)	86	1.39 (1.11-1.71)**
15+	156	0.86 (0.73-1.01)	17	0.98 (0.57-1.57)	28	1.57 (1.05-2.27)*
	Trend across categories P=0.01		Trend across categories P=0.12		Trend across categories P=0.74	

Table 4. Standardized incidence ratios for invasive and in-situ breast cancer and invasive and borderline tumours of the ovary among 255,786 women who underwent assisted reproduction in Great Britain, 1991-2010.

Factor [¶]	Invasive Breast Cancer ^{**}		In-situ Breast Cancer ^{**}		Invasive Ovarian Tumours ^{§§}		Borderline Ovarian Tumours	
	Observed	SIR (95%CI)	Observed	SIR (95%CI)	Observed	SIR (95% CI)	Observed	SIR (95%CI)
Overall	2272	0.96 (0.92-1.00)*	291	1.15 (1.02-1.29)*	264	1.40 (1.24-1.58)***	141	1.36 (1.15-1.60)**
Age at first treatment (years)								
<25	14	1.43 (0.78-2.39)	0	0.00 (0.00-4.34)	<5	#	<5	#
25-29	168	0.91 (0.78-1.06)	16	1.10 (0.63-1.78)	35	2.33 (1.63-3.25)***	29	1.98 (1.33-2.85)**
30-34	685	0.92 (0.86-1.00)*	85	1.27 (1.02-1.57)*	81	1.46 (1.16-1.82)**	61	1.61 (1.23-2.07)**
35-39	925	0.97 (0.91-1.04)	100	0.94 (0.77-1.15)	97	1.32 (1.07-1.61)*	37	1.04 (0.73-1.43)
40-44	411	1.00 (0.90-1.10)	66	1.23 (0.95-1.56)	40	1.13 (0.80-1.53)	10	0.82 (0.39-1.50)
45+	69	0.94 (0.73-1.19)	24	2.12 (1.36-3.15)**	<10	#	<5	#
	Trend across categories P=0.30		Trend across categories P=0.47		Trend across categories P=0.02		Trend across categories P<0.001	
Infertility cause								
Any female factor	1118	0.92 (0.87-0.98)**	151	1.14 (0.97-1.34)	161	1.66 (1.41-1.94)***	85	1.66 (1.33-2.05)***
Male factor only	676	0.89 (0.83-0.96)**	93	1.18 (0.95-1.44)	65	1.09 (0.84-1.39)	33	0.96 (0.66-1.35)
Unexplained	374	1.10 (0.99-1.22)	42	1.18 (0.85-1.59)	26	0.98 (0.64-1.44)	14	0.92 (0.50-1.55)
Unrecorded	104	1.58 (1.30-1.92)***	5	0.73 (0.24-1.70)	12	2.35 (1.21-4.10)*	9	3.00 (1.37-5.70)*
History of endometriosis								
Yes	186	0.95 (0.82-1.10)	26	1.25 (0.81-1.83)	38	2.47 (1.75-3.39)***	17	2.03 (1.18-3.25)*
No	2086	0.96 (0.92-1.00)	265	1.14 (1.01-1.28)*	226	1.31 (1.14-1.49)***	124	1.30 (1.08-1.55)**
History of tubal disease								
Yes	725	0.94 (0.87-1.01)	92	1.11 (0.89-1.36)	105	1.71 (1.40-2.08)***	53	1.62 (1.21-2.12)*
No	1547	0.97 (0.92-1.01)	199	1.17 (1.01-1.34)*	159	1.25 (1.07-1.46)**	88	1.24 (0.99-1.53)
History of ovulatory problems								
Yes	315	0.91 (0.81-1.02)	41	1.05 (0.75-1.42)	33	1.16 (0.80-1.63)	22	1.52 (0.96-2.31)
No	1957	0.97 (0.92-1.01)	250	1.17 (1.03-1.32)*	231	1.45 (1.27-1.65)***	119	1.33 (1.11-1.60)**
Duration of infertility at last cycle (years)								

	< 2	156	0.97 (0.83-1.14)	15	0.82 (0.46-1.35)	16	1.23 (0.70-1.99)	12	1.89 (0.98-3.30)
	2-3	464	1.03 (0.94-1.13)	61	1.26 (0.97-1.62)	53	1.48 (1.11-1.93)*	20	0.99 (0.61-1.53)
	4-5	461	0.97 (0.89-1.07)	52	1.03 (0.77-1.35)	53	1.42 (1.06-1.85)*	21	1.02 (0.63-1.55)
	6-7	278	0.90 (0.79-1.01)	35	1.03 (0.72-1.44)	40	1.63 (1.16-2.21)**	20	1.57 (0.96-2.42)
	8-9	169	0.92 (0.78-1.06)	27	1.31 (0.86-1.91)	27	1.84 (1.21-2.67)**	9	1.24 (0.57-2.36)
	10+	279	0.92 (0.82-1.04)	42	1.15 (0.83-1.56)	40	1.60 (1.14-2.18)**	17	1.61 (0.94-2.58)
	Unrecorded	355	1.05 (0.94-1.16)	48	1.37 (1.01-1.82)*	25	0.97 (0.63-1.43)	17	1.12 (0.65-1.79)
			Trend across categories P=0.11		Trend across categories P=0.58		Trend across categories P=0.25		Trend across categories P=0.42
Total number of stimulated cycles									
	0 – 'natural cycle' only	121	0.85 (0.71-1.02)	21	1.14 (0.71-1.74)	13	1.04 (0.55-1.78)	<5	#
	1	1073	0.97 (0.91-1.03)	121	1.02 (0.85-1.22)	129	1.47 (1.23-1.75)***	67	1.39 (1.08-1.77)*
	2	512	0.98 (0.90-1.07)	70	1.25 (0.97-1.58)	56	1.37 (1.03-1.78)*	31	1.40 (0.95-1.98)
	3-4	371	1.01 (0.92-1.12)	47	1.18 (0.87-1.57)	42	1.48 (1.06-1.99)*	11	0.75 (0.37-1.33)
	5+	85	0.96 (0.77-1.91)	21	2.11 (1.31-3.23)**	14	2.04 (1.11-3.42)*	<5	#
			Trend across categories P=0.27		Trend across categories P=0.03*		Trend across categories P=0.29		Trend across categories P=0.18
Total number of live births after last treatment									
	0	1154	0.98 (0.92-1.04)	135	1.04 (0.87-1.23)	156	1.67 (1.42-1.95)***	66	1.38 (1.07-1.75)*
	1	732	0.99 (0.92-1.07)	107	1.37 (1.12-1.65)**	78	1.34 (1.06-1.67)*	36	1.09 (0.76-1.51)
	2+	276	0.90 (0.80-1.02)	37	1.07 (0.76-1.48)	20	0.81 (0.50-1.26)	14	1.16 (0.63-1.95)
	Unrecorded	0	0.00	1	20.00 (0.51-111.43)	0	0.00 (0.00-74.89)	0	0.0 (0.0-149.79)
			Trend across categories P=0.37		Trend across categories P=0.32		Trend across categories P=0.001		Trend across categories P=0.34
Any multiple birth recorded									
	Yes	234	1.10 (0.97-1.25)	22	1.05 (0.66-1.58)	22	1.34 (0.84-2.03)	11	1.06 (0.53-1.90)
	No	1928	0.96 (0.92-1.00)	258	1.16 (1.02-1.31)*	232	1.45 (1.27-1.65)***	105	1.27 (1.04-1.54)*
Time since last treatment (years)									
	0-3	488	1.05 (0.96-1.15)	37	1.06 (0.71-1.39)	62	1.73 (1.33-2.22)***	37	1.30 (0.92-1.79)
	3-6	476	1.03 (0.94-1.12)	51	1.24 (0.93-1.63)	45	1.27 (0.93-1.71)	28	1.27 (0.85-1.84)
	6-10	556	0.94 (0.87-1.02)	95	1.52 (1.23-1.85)***	63	1.37 (1.05-1.75)*	21	0.96 (0.59-1.46)
	10+	510	0.93 (0.85-1.01)	75	0.98 (0.77-1.22)	63	1.38 (1.06-1.77)*	23	1.39 (0.88-2.08)
	15+	132	0.86 (0.72-1.02)	22	0.85 (0.54-1.29)	21	1.52 (0.94-2.32)	7	1.75 (0.70-3.60)
			Trend across categories P=0.005**		Trend across categories P=0.29		Trend across categories P=0.44		Trend across categories P=0.84

Table 5. Standardized incidence ratios for all ovarian cancers, invasive and borderline ovarian tumours among 225,786 women who underwent assisted reproduction in Great Britain, 1991–2010, by presence or absence of known risk factors endometriosis and nulliparity.

Factor	Type of ovarian cancer					
	All ovarian cancer ^{II}		Invasive cancer ^{SS}		Borderline tumours ^{III}	
	Observed Cancers	SIR (95%CI)	Observed cancers	SIR (95%CI)	Observed cancers	SIR (95%CI)
No diagnosis of endometriosis and at least one birth recorded by treatment completion	133	1.03 (0.86-1.22)	85	1.03 (0.82-1.27)	48	1.02 (0.75-1.35)
No diagnosis of endometriosis and no births recorded by treatment completion	217	1.57 (1.37-1.79)***	141	1.56 (1.32-1.84)***	76	1.57 (1.24-1.97)***
Diagnosis of endometriosis and at least one birth recorded by treatment completion	24	2.41 (1.55-3.59)***	14	2.22 (1.21-3.72)*	10	2.76 (1.33-5.08)*
Diagnosis of endometriosis and no birth recorded by treatment completion	31	2.24 (1.52-3.18)***	24	2.64 (1.69-3.93)***	7	1.47 (0.59-3.04)

Table Legends

† Absolute Excess Risk per 100,000 person years at risk

‡ 'Breast Cancer'= ICD-9: 1740-9, 2330, 2383; ICD-10: C500-9, D050-9, D486

§ 'Corpus Uteri Cancer'= ICD-9: 1820-8; ICD-10: C54

|| 'Ovarian Cancer'= ICD-9: 1830-1839, 2362; ICD-10: C56, C570-C574, C481, C482, D391

* $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$

[¶] See Supplemental Data for results excluding the first 12 months of follow up.

^{††} 'Invasive Breast Cancer'= ICD-9: 1740-9; ICD-10: C500-9

^{†††} 'In-situ Breast Cancer'= ICD-9: 2330; ICD-10: D050-9

^{§§} 'Invasive Ovarian Tumours'= ICD-9: 1830-1839 (excluding morphology codes

8442/8451/8462/8472/8473) 2362; ICD-10: C56, C570-C574, C481, C482 (excluding

morphology codes 8442/8451/8462/8472/8473).

^{|||} 'Borderline Ovarian Tumours'= ICD-9 1830 (with morphology codes

8442/8451/8462/8472/8473); ICD-10 D391, C56 (with morphology codes


8442/8451/8462/8472/8473).

SIRs suppressed to comply with data disclosure regulations where cells relate to small

numbers of individuals. None of the SIRs for affected cells approached significance.

Suggested supplementary appendix

Figure S1- Flow diagram of cohort records



Box S1- Details of linkage & analysis**Details of linkage at National Health Service-Digital and National Records for Scotland**

Matching was initially deterministic, matching on:-

- Forename, Surname
- 2 of 3 parts of date of birth match

If more than one match was found no match was accepted and the records would go for manual matching along with unmatched records. Manual matching utilised: -

- Forename, Surname, Date of birth
- Other recorded names
- Place of birth
- Treatment centre/ Cycle date

Quality control process: -

Automatic matching algorithm used (A) was tested against an algorithm using exact date of birth match (B). Both A and B were performed on 4239 cases. The 4239 cases then underwent manual matching gold standard.

A – 0/4239 false positive matches

B – 9/4239 false positive matches

Additional details of analysis: -


As detailed in the main paper, expected cancers were calculated by multiplying person-years at risk by corresponding national incidence rates (by 5-year age band and individual calendar year) for the general population of England & Wales. Annual national incidence rates 1991-1998 are for England and Wales, thereafter national rates refer to England only as rates were not published for England and Wales.

Table S1. Meta-data for available HFEA variables (linked cohort)

HFEA data item	Frequency	Details	Data Source	% complete
Date of Birth	255,786		Self-reported to HFEA	100
Ethnic group	46,107	30 potential responses	Self-reported to HFEA	18.0
Start date of first treatment cycle	255,786	Year of each treatment cycle recorded. Year mid-point used to calculate person-years at risk.	Clinic reported to HFEA	100
Start date of last treatment cycle	255,786		Clinic reported to HFEA	100
Age at first treatment	255,786	Categorised: - <25 yrs- 5,671 25-29 yrs- 39,932 30-34 yrs- 92,788 35-39 yrs- 85,868 40-44 yrs- 28,174 45+yrs - 3,353	Derived, first treatment cycle date minus date of birth	100
Broad Cause of infertility	244,286	Female- 70,293 Male- 84,871 Both- 41,365 Unexplained- 47,757 Unrecorded- 11,500 & all specific causes negative.	Clinic reported to HFEA	95.5
Endometriosis	255,786	Yes- 18,630 No- 237,156	Clinic reported to HFEA	100
Tubal disease	255,786	Yes- 66,370 No- 189,416	Clinic reported to HFEA	100
Ovulatory disorder	255,786	Yes- 36,016 No- 219,770	Clinic reported to HFEA	100
Male factor infertility	255,786	Any Yes-126,236 No-129,550 Sperm concentration Yes- 18,679 No-237,107 Sperm morphology Yes-10,586 No-245,200 Sperm motility Yes-9,263 No-246,523 Sperm immune issue Yes-2,493 No-253,293	Clinic reported to HFEA	
Primary Female infertility	255,576	Yes-113,918 No- 141,658 Unrecorded-210	Clinic reported to HFEA	99.9
Secondary Female Infertility	255,786	Yes-86,322 No-169,464	Clinic reported to HFEA	100
Primary Male Infertility	255,786	Yes-117,207 No-138,579	Clinic reported to HFEA	100
Secondary Male Infertility	255,786	Yes-80,843 No-174,943	Clinic reported to HFEA	100
Primary Couple infertility	255,786	Yes-139,272 No-116,514	Clinic reported to HFEA	100
Secondary Couple infertility	255,786	Yes-58,584 No-197,202	Clinic reported to HFEA	100
Duration of infertility	206,304	<2yrs- 17,194 2-3yrs- 67,529 4-5yrs- 56,203 6-7yrs- 29,946 8-9yrs - 15,394 >=10yrs -20,038 Unrecorded- 49,482	Self-reported to HFEA	80.6

Number of Treatment cycles	255,778	Natural cycle only-9,781 Stimulated cycles- 1- 131,670 2- 63,842 3-4- 41,224 5+ - 9,261 Unrecorded - 8	Clinic reported to HFEA	99.9
Type of ART treatment	255,177	IVF only- 150,700 ICSI/ Unspecified micromanipulation- 76, 596 IVF & ICSI- 27,881	Clinic reported to HFEA	99.8
Treatment centre	255,786	Treatment centre only geographical variable available	Clinic reported to HFEA	100
Number of Pregnancies by end of last treatment cycle	255,377	0- 82,747 1- 94,836 2-3- 63,821 4-5- 11,246 6+ 2,727 Unknown - 409	Derived variable from self-reported pregnancies on registration of last treatment cycle plus HFEA recorded ART pregnancies from last treatment cycle (validated against HFEA recorded ART pregnancies from previous cycles).	99.8
Years since last pregnancy	121,698	Variable contains a number of values which are likely to be age at last pregnancy.	Self-reported to HFEA	47.6
Age at last pregnancy	121,698	Median- 31.7 yrs IQR 35.5-27.7 yrs	Self-reported to HFEA	47.6
Number of live births by end of last treatment cycle	255,701	0- 129,217 1- 96,839 2-3- 27,593 4+ 2,052 Unrecorded- 85	Derived variable from self-reported births on registration of last treatment cycle plus HFEA recorded ART birth from last treatment cycle (validated against HFEA recorded ART births from previous cycles).	99.9
Multiple births	255,786	Yes- 29,366 No- 29,366	Clinic reported to HFEA	100
ART birth recorded by HFEA	255,786	Yes- 105,183 No-150,183	Clinic reported to HFEA	100

Figure S2- Person years of follow up within the cohort of women who had assisted conception, by year of first treatment



Review Only

Table S2- Cohort frequency and person years of follow up by year of first

Year of first treatment	No. of women	%	Cumulative %	Person-years of follow-up	Person-years as % of total	Cumulative person years as % of cohort
1991	5,047	2.0	1.97	95654	4.2	4.2
1992	9,169	3.6	5.56	165557	7.3	11.6
1993	9,095	3.6	9.11	155957	6.9	18.5
1994	9,996	3.9	13.02	162009	7.2	25.7
1995	11,216	4.4	17.41	171479	7.6	33.3
1996	12,004	4.7	22.10	172036	7.6	40.9
1997	12,124	4.7	26.84	161905	7.2	48.1
1998	12,578	4.9	31.76	156201	6.9	55.0
1999	12,058	4.7	36.47	138110	6.1	61.1
2000	12,149	4.8	41.22	127788	5.7	66.8
2001	12,622	4.9	46.15	120568	5.3	72.1
2002	12,932	5.1	51.21	110950	4.9	77.0
2003	12,414	4.9	56.06	94329	4.2	81.2
2004	14,368	5.6	61.68	95264	4.2	85.4
2005	15,144	5.9	67.60	85673	3.8	89.2
2006	17,130	6.7	74.30	80136	3.6	92.7
2007	18,070	7.1	81.36	66809	3.0	95.7
2008	20,494	8.0	89.38	55464	2.5	98.2
2009	22,068	8.6	98.00	38141	1.7	99.9
2010	5,108	2.0	100.00	3760	0.2	100.0
Total	255,786	100.0	100.00	2257789	100.0	100.0

Table S3- Sensitivity analysis excluding the first 12 months of follow up for breast, corpus uteri and ovarian cancer

Factor	Type of Cancer					
	Breast [‡]		Corpus Uteri [§]		Ovarian	
	Observed Cancers	SIR (95%CI)	Observed Cancers	SIR (95%CI)	Observed Cancers	SIR (95%CI)
Overall	2384	0.95 (0.92-0.99)*	157	1.12 (0.94-1.30)	356	1.31 (1.18-1.45)***
Age at first treatment (years)						
<25	11	1.05 (0.53-1.88)	0	0.00 (0.00-7.13)	<5	#
25-29	171	0.87 (0.74-1.01)	8	1.01 (0.44-2.00)	55	1.99 (1.50-2.59)***
30-34	723	0.92 (0.86-0.99)*	41	1.16 (0.83-1.58)	124	1.42 (1.18-1.69)***
35-39	955	0.95 (0.89-1.02)	70	1.23 (0.96-1.55)	118	1.16 (0.96-1.39)
40-44	436	1.01 (0.92-1.11)	32	0.97 (0.67-1.37)	47	1.07 (0.78-1.42)
45+	88	1.13 (0.91-1.39)	6	0.71 (0.26-1.56)	<10	#
	Trend across categories P=0.03		Trend across categories P=0.54		Trend across categories P=0.001	
Infertility cause						
Any female factor	1224	0.95 (0.90-1.00)	95	1.26 (1.02-1.54)*	221	1.58 (1.38-1.81)***
Male factor only	727	0.91 (0.85-0.98)**	40	0.92 (0.66-1.25)	88	1.01 (0.81-1.24)
Unexplained	377	1.08 (0.98-1.20)	16	0.83 (0.47-1.35)	33	0.88 (0.60-1.23)
Unrecorded	56	0.87 (0.66-1.13)	6	1.67 (0.61-3.64)	14	1.98 (1.08-3.33)*
History of endometriosis						
Yes	204	0.98 (0.85-1.12)	9	0.78 (0.35-1.47)	49	2.19 (1.62-2.89)***
No	2180	0.95 (0.91-0.99)*	148	1.14 (0.96-1.34)	307	1.23 (1.10-1.38)**
History of tubal disease						
Yes	800	0.97 (0.90-1.04)	57	1.21 (0.92-1.57)	151	1.69 (1.44-1.99)***
No	1584	0.95 (0.90-0.99)*	100	1.06 (0.86-1.28)	205	1.12 (0.97-1.29)
History of ovulatory problems						
Yes	333	0.91 (0.82-1.02)	38	1.65 (1.17-2.27)**	43	1.08 (0.78-1.45)
No	2051	0.96 (0.92-1.00)	119	1.00 (0.83-1.20)	313	1.35 (1.20-1.51)***
Duration of infertility at last treatment cycle (years)						
< 2	142	0.84 (0.71-1.00)	<5	## *	23	1.26 (0.82-1.93)
2-3	481	1.04 (0.95-1.14)	22	0.83 (0.52-1.26)	62	1.23 (0.94-1.57)
4-5	498	1.00 (0.92-1.10)	30	1.07 (0.73-1.54)	66	1.23 (0.95-1.57)
6-7	298	0.91 (0.81-1.02)	27	1.43 (0.94-2.07)	57	1.63 (1.24-2.12)**
8-9	185	0.94 (0.81-1.08)	16	1.38 (0.79-2.24)	33	1.60 (1.10-2.24)†
10+	305	0.94	37	1.72	50	1.49

	Unrecorded	360 (0.84-1.05) 1.06 (0.95-1.17) Trend across categories P=0.47	<20 # (1.21-2.38)** Trend across categories P<0.001	36 0.99 (1.10-1.96) [†] (0.69-1.37) Trend across categories P=0.13
Total number of stimulated cycles				
	0 – 'natural cycle' only	136 0.90 (0.76-1.07)	8 0.68 (0.30-1.35)	15 0.94 (0.53-1.55)
	1	1107 0.96 (0.90-1.01)	85 1.29 (1.03-1.59)*	174 1.39 (1.19-1.61)***
	2	545 1.01 (0.93-1.10)	29 0.95 (0.64-1.37)	77 1.33 (1.05-1.67)*
	3-4	381 1.01 (0.91-1.11)	24 1.12 (0.72-1.66)	48 1.22 (0.90-1.61)
	5+	100 1.10 (0.90-1.34)	5 0.94 (0.31-2.19)	13 1.41 (0.75-2.41)
	Unrecorded	0 0.00 (0.00-33.29) Trend across categories P=0.13	0 0.00 (0.00-299.57) Trend across categories P=0.81	0 0.00 (0.00-299.57) Trend across categories P=0.95
Total number of live births at last cycle completion				
	0	1166 0.95 (0.89-1.00)	116 1.60 (1.32-1.92)***	189 1.45 (1.25-1.67)***
	1	801 1.04 (0.97-1.12)	24 0.56 (0.36-0.83)**	109 1.31 (1.07-1.58)**
	2+	301 0.94 (0.84-1.05)	11 0.56 (0.28-1.00)*	29 0.86 (0.57-1.23)
	Unrecorded	1 2.13 (0.05-11.86) Trend across categories P=0.48	0 0.00 (0.00-99.86) Trend across categories P<0.001	0 0.00 (0.00-59.92) Trend across categories P=0.01
Multiple birth as recorded at last cycle completion				
	Yes	253 1.15 (1.01-1.30)*	5 0.44 (0.14-1.03)*	31 1.26 (0.86-1.79)
	No	2016 0.96 (0.92-1.00)	146 1.18 (1.00-1.39)	296 1.33 (1.18-1.49)***
Time since last treatment (years)				
	0-3	337 0.99 (0.88-1.10)	22 1.58 (0.99-2.39)	56 1.32 (1.00-1.71)
	3-6	529 1.04 (0.95-1.13)	29 1.28 (0.85-1.83)	73 1.27 (1.00-1.60)
	6-10	657 1.00 (0.93-1.08)	38 1.07 (0.76-1.47)	84 1.24 (0.99-1.53)
	10-15	590 0.93 (0.86-1.01)	45 0.99 (0.72-1.33)	86 1.39 (1.11-1.71)**
	15+	156 0.86 (0.73-1.01) Trend across categories P=0.06	17 0.98 (0.57-1.57) Trend across categories P=0.06	28 1.57 (1.04-2.27)* Trend across categories P=0.46

Table S4- Sensitivity analysis excluding the first 12 months of follow up for invasive and borderline ovarian tumours

Factor	Invasive Ovarian Tumours ^{§§}		Borderline Ovarian Tumours	
	Observed Cancers	SIR (95%CI)	Observed Cancers	SIR (95%CI)
Overall	244	1.37 (1.21-1.56)***	112	1.19 (0.98-1.43)
Age at first treatment (years)				
<25	<5	#	<5	#
25-29	32	2.24 (1.53-3.16)***	23	1.72 (1.09-2.58)*
30-34	76	1.44 (1.13-1.80)**	48	1.39 (1.02-1.84)*
35-39	87	1.25 (1.01-1.55)*	31	0.96 (0.65-1.37)
40-44	39	1.17 (0.83-1.60)	8	0.74 (0.32-1.46)
45+	<10	#	<5	#
	Trend across categories P=0.01		Trend across categories P=0.01	
Infertility cause				
Any female factor	155	1.67 (1.42-1.96)***	66	1.40 (1.09-1.79)*
Male factor only	60	1.06 (0.81-1.37)	28	0.90 (0.60-1.30)
Unexplained	20	0.82 (0.50-1.27)	13	0.98 (0.52-1.67)
Unrecorded	9	1.99 (0.91-3.78)	5	1.98 (0.64-4.61)
History of endometriosis				
Yes	37	2.51 (1.77-3.47)***	12	1.57 (0.81-2.73)
No	207	1.27 (1.10-1.45)**	100	1.16 (0.94-1.41)
History of tubal disease				
Yes	101	1.72 (1.40-2.09)***	50	1.65 (1.23-2.18)**
No	143	1.20 (1.01-1.42)*	62	0.97 (0.75-1.25)
History of ovulatory problems				
Yes	32	1.19 (0.82-1.61)	11	0.84 (0.42-1.51)
No	212	1.40 (1.22-1.61)***	101	1.25 (1.02-1.52)*
Duration of infertility at last treatment cycle (years)				
< 2	15	1.23 (0.69-2.02)	8	1.41 (0.61-2.79)
2-3	47	1.43 (1.05-1.90)*	15	0.85 (0.48-1.41)
4-5	49	1.40 (1.03-1.85)*	17	0.92 (0.54-1.47)
6-7	39	1.67 (1.19-2.29)**	18	1.55 (0.92-2.45)
8-9	25	1.78 (1.15-2.63)*	8	1.21 (0.52-2.37)
10+	35	1.46 (1.02-2.03)*	15	1.55 (0.87-2.55)
Unrecorded	21	0.90 (0.56-1.38)	15	1.13 (0.63-1.87)
	Trend across categories P=0.39		Trend across categories P=0.17	

Total number of stimulated cycles				
0 – 'natural cycle' only	13	1.11 (0.59-1.90)	<5	#
1	118	1.43 (1.19-1.72)***	56	1.30 (0.98-1.69)
2	50	1.32 (0.98-1.73)	27	1.37 (0.90-1.99)
3-4	39	1.48 (1.05-2.02)*	9	0.69 (0.32-1.31)
5+	11	1.74 (0.87-3.11)	<5	#
Trend across categories P=0.48			Trend across categories P=0.30	
Total number of live births at last cycle completion				
0	136	1.55 (1.30-1.84)***	53	1.24 (0.93-1.62)
1	77	1.42 (1.12-1.78)**	32	1.09 (0.75-1.54)
2+	18	0.78 (0.46-1.23)	11	1.01 (0.51-1.81)
Unrecorded	0	0.00 (0.00-99.86)	0	0.00 (0.00-149.8)
Trend across categories P=0.01			Trend across categories P=0.46	
Multiple birth as recorded at last cycle completion				
Yes	21	1.37 (0.85-2.09)	10	1.08 (0.52-1.99)
No	210	1.41 (1.22-1.61)***	86	1.17 (0.93-1.44)
Time since last treatment (years)				
0-3	39	1.62 (1.15-2.21)**	17	0.93 (0.54-1.48)
3-6	45	1.27 (0.93-1.71)	28	1.27 (0.85-1.84)
6-10	63	1.37 (1.05-1.75)*	21	0.96 (0.59-1.46)
10-15	63	1.38 (1.06-1.77)*	23	1.39 (0.88-2.08)
15+	21	1.52 (0.94-2.32)	7	1.75 (0.70-3.60)
Trend across categories P=0.85			Trend across categories P=0.21	

Table S5- Sensitivity analysis excluding the first 12 months of follow up for invasive and in-situ breast cancer

Factor	Invasive breast cancer ^{††}		In situ- breast cancer ^{††}	
	Obs. Cancers	SIR (95%CI)	Obs. Cancers	SIR (95%CI)
Overall	2089	0.93 (0.89-0.97)**	280	1.15 (1.02-1.29)*
Age at first treatment (years)				
<25	11	1.14 (0.57-2.04)	0	0.00 (0.00-4.41)
25-29	154	0.85 (0.72-1.00)*	16	1.12 (0.64-1.81)
30-34	635	0.89 (0.82-0.96)**	84	1.29 (1.03-1.59)*
35-39	850	0.95 (0.89-1.02)	97	0.95 (0.77-1.16)
40-44	373	0.99 (0.89-1.09)	61	1.19 (0.91-1.53)
45+	66	0.99 (0.76-1.26)	22	2.06 (1.29-3.12)**
		Trend across categories P=0.07		Trend across categories P=0.67
Infertility cause				
Any female factor	1068	0.93 (0.87-0.98)**	146	1.14 (0.96-1.34)
Male factor only	632	0.88 (0.81-0.95)**	90	1.18 (0.95-1.45)
Unexplained	337	1.08 (0.97-1.20)	<45	#
Unrecorded	52	0.90 (0.67-1.18)	<5	#
History of endometriosis				
Yes	176	0.94 (0.81-1.09)	26	1.28 (0.84-1.88)
No	1913	0.93 (0.89-0.97)**	254	1.13 (1.00-1.28)
History of tubal disease				
Yes	701	0.95 (0.88-1.02)	90	1.11 (0.89-1.36)
No	1388	0.92 (0.87-0.97)**	190	1.17 (1.01-1.34)*
History of ovulatory problems				
Yes	294	0.90 (0.80-1.01)	38	1.01 (0.72-1.39)
No	1795	0.94 (0.89-0.98)**	242	1.17 (1.03-1.33)*
Duration of infertility at last treatment cycle (years)				
< 2	128	0.85 (0.71-1.02)	14	0.80 (0.44-1.34)
2-3	422	1.02 (0.92-1.12)	57	1.25 (0.95-1.63)
4-5	439	0.99 (0.90-1.08)	52	1.08 (0.80-1.41)
6-7	260	0.88 (0.78-1.00)*	35	1.07 (0.75-1.49)
8-9	159	0.90 (0.77-1.06)	25	1.25 (0.81-1.85)
10+	262	0.91 (0.80-1.03)	42	1.19 (0.86-1.60)
Unrecorded	311	1.02 (0.91-1.14)	48	1.49 (1.10-1.97)*
		Trend across categories P=0.30		Trend across categories P=0.53

Total number of stimulated cycles					
	0 – 'natural cycle' only	115	0.87 (0.72-1.04)	21	1.20 (0.74-1.83)
	1	981	0.95 (0.89-1.01)	117	1.03 (0.85-1.23)
	2	472	0.97 (0.89-1.07)	70	1.32 (1.03-1.66)*
	3-4	334	0.99 (0.88-1.10)	45	1.19 (0.87-1.60)
	5+	79	0.98 (0.77-1.22)	20	2.14 (1.31-3.31)**
	Unrecorded	0	0.00 (0.00-37.45)	0	0.00 (0.00-299.57)
			Trend across categories P=0.27		Trend across categories P=0.03*
Total number of live births at last cycle completion					
	0	1027	0.94 (0.88-0.99)*	129	1.04 (0.87-1.23)
	1	691	1.00 (0.93-1.08)	106	1.43 (1.17-1.72)**
	2+	263	0.92 (0.81-1.04)	37	1.12 (0.79-1.55)
	Unrecorded	0	0.00 (0.00-7.13)	1	20.00 (0.51-111.43)
			Trend across categories P=0.71		Trend across categories P=0.21
Any multiple birth as recorded at last cycle completion					
	Yes	230	1.16 (1.01-1.32)*	21	1.04 (0.65-1.59)
	No	1751	0.93 (0.89-0.98)**	252	1.19 (1.05-1.35)**
Time since last treatment (years)					
	0-3	307	0.98 (0.87-1.09)	30	1.18 (0.80-1.69)
	3-6	476	1.03 (0.94-1.12)	51	1.24 (0.93-1.63)
	6-10	556	0.94 (0.87-1.02)	95	1.52 (1.23-1.85)***
	10-15	510	0.93 (0.85-1.01)	75	0.98 (0.77-1.22)
	15+	132	0.86 (0.72-1.02)	22	0.85 (0.54-1.29)
			Trend across categories P=0.07		Trend across categories P=0.07

Table S6- Risk of any ovarian cancer, invasive and borderline ovarian tumours in women with and without endometriosis and or nulliparity, stratified by age at first treatment

Factor	Type of ovarian tumour					
	All ovarian tumours ^{II}		Invasive ovarian tumour ⁵⁵		Borderline ovarian tumour ^{III}	
	Observed Cancers	SIR (95%CI)	Observed Cancers	SIR (95%CI)	Observed Cancers	SIR (95%CI)
Age at first treatment if at least one risk factor (endometriosis, nulliparity) recorded						
<25 years	<5	#	<5	#	<5	#
25-29 years	44	2.84 (2.06-3.81)***	26	3.28 (2.14-4.80)***	18	2.37 (1.40-3.74)**
30-34 years	97	1.97 (1.60-2.40)***	55	1.86 (1.40-2.43)***	42	2.13 (1.54-2.88)***
35-39 years	93	1.50 (1.21-1.84)***	70	1.67 (1.30-2.11)***	23	1.15 (0.73-1.72)
40-44 years	33	1.11 (0.76-1.56)	24	1.09 (0.70-1.61)	9	1.17 (0.54-2.23)
45+ years	<5	#	<5	#	<5	#
	Trend across categories P<0.001		Trend across categories P<0.001		Trend across categories P=0.01	
Age at first treatment if no risk factors recorded						
<25 years	<5	#	<5	#	<5	#
25-29 years	20	1.42 (0.87-2.19)	<10	#	11	1.57 (0.78-2.80)
30-34 years	45	1.02 (0.75-1.37)	26	1.01 (0.66-1.48)	19	1.05 (0.63-1.63)
35-39 years	41	0.87 (0.62-1.18)	27	0.86 (0.57-1.25)	14	0.89 (0.49-1.50)
40-44 years	17	0.94 (0.55-1.51)	16	1.19 (0.68-1.93)	<5	#
45+ years	<10	#	5	1.21 (0.39-2.82)	<5	#
	Trend across categories P=0.07		Trend across categories P=0.62		Trend across categories P=0.02	

Box S2- Investigation of women with unrecorded cause of infertility

Investigation of women with unrecorded cause of infertility (n= 11,500)

Women with unrecorded cause of infertility had significantly increased rates of breast, ovarian and corpus uteri cancer. Reasons for this are unclear. Those with unrecorded cause of infertility had treatment more recently, at older ages, with fewer cycles, shorter duration of infertility, more 'freeze-all' cycles (data for 'freeze-all' cycles are available for only a sub-set of our cohort; women who had children after assisted conception between 1992 and 2008). Women with unrecorded cause of infertility had a higher cancer incidence within the first 12 months.

Variable	Whole cohort average (95%CI)	Unrecorded cause of infertility cohort average (95%CI)	Test statistic
First treatment year	2002.0 (2002.0-2002.1)	2005.5 (2005.4-2005.5)	P<0.001
Age at first treatment (years)	34.4 (34.4-34.4)	36.3 (36.2-36.4)	P<0.001
Number of treatment cycles	1.77 (1.76 -1.77)	1.51 (1.49-1.53)	P<0.001
Duration of infertility at last treatment cycle	4.90 (4.89-4.92)	3.69 (3.62-3.77)	P<0.001
'Freeze -all' cycle	11.9% (11.7-12.1)	13.2% (12.1-14.8)	-
Proportion of cancers diagnosed within 12months of first treatment.	6.2% (5.3-7.0)	45.7% (37.5-54.0)	P<0.001

Therefore excess risk in this sub-group might be due to reverse causation; cancer and/or related treatment causing infertility rather than arising as a result of infertility or its treatment. Whilst we excluded all women with a cancer diagnosis in calendar years before first treatment year, we could not exclude women diagnosed in the same calendar year as first treatment because exact treatment date was unavailable. As some results remained significant after excluding the first 12 months of follow up, there may be further explanations. Unfortunately study regulations preclude inspection of clinical notes to investigate further.

Table Legends for appendix

[†] Absolute Excess Risk per 100,000 person years at risk

[‡] 'Breast Cancer'= ICD-9: 1740-9, 2330, 2383; ICD-10: C500-9, D050-9, D486

[§] 'Corpus Uteri Cancer'= ICD-9: 1820-8; ICD-10: C54

^{||} 'Ovarian Cancer'= ICD-9: 1830-1839, 2362; ICD-10: C56, C570-C574, C481, C482, D391

* $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$

[¶] See Supplemental Data for results excluding the first 12 months of follow up.

^{††} 'Invasive Breast Cancer'= ICD-9: 1740-9; ICD-10: C500-9

^{†††} 'In-situ Breast Cancer'= ICD-9: 2330; ICD-10: D050-9

^{§§} 'Invasive Ovarian Tumours'= ICD-9: 1830-1839 (excluding morphology codes

8442/8451/8462/8472/8473) 2362; ICD-10: C56, C570-C574, C481, C482 (excluding morphology codes 8442/8451/8462/8472/8473).

^{|||} 'Borderline Ovarian Tumours'= ICD-9 1830 (with morphology codes

8442/8451/8462/8472/8473); ICD-10 D391, C56 (with morphology codes 8442/8451/8462/8472/8473).

[#] SIRs suppressed to comply with data disclosure regulations where cells relate to small numbers of individuals. None of the SIRs for affected cells approached significance.

^{##} SIR suppressed to comply with data disclosure regulations where cells relate to small numbers of individuals. SIR was significantly lower than age standardised expectation ($P=0.014$).

REFERENCES

1. Fathalla MF: Incessant ovulation--a factor in ovarian neoplasia? *Lancet* 2:163, 1971
2. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. *Cancer Res* 48:246-53, 1988
3. Rossing MA, Daling JR, Weiss NS, et al: Ovarian tumors in a cohort of infertile women. *N Engl J Med* 331:771-6, 1994
4. Venn A, Watson L, Bruinsma F, et al: Risk of cancer after use of fertility drugs with in-vitro fertilisation. *Lancet* 354:1586-90, 1999
5. Brinton LA, Trabert B, Shalev V, et al: In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. *Fertil Steril* 99:1189-96, 2013
6. Kallen B, Finnstrom O, Lindam A, et al: Malignancies among women who gave birth after in vitro fertilization. *Hum Reprod* 26:253-8, 2011
7. Yli-Kuha AN, Gissler M, Klemetti R, et al: Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. *Hum Reprod* 27:1149-55, 2012
8. Luke B, Brown MB, Spector LG, et al: Cancer in women after assisted reproductive technology. *Fertil Steril* 104:1218-26, 2015
9. Pappo I, Lerner-Geva L, Halevy A, et al: The possible association between IVF and breast cancer incidence. *Ann Surg Oncol* 15:1048-55, 2008
10. Sergantianis TN, Diamantaras AA, Perlepe C, et al: IVF and breast cancer: a systematic review and meta-analysis. *Hum Reprod Update* 20:106-23, 2014
11. Gennari A, Costa M, Puntoni M, et al: Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. *Breast Cancer Res Treat* 150:405-13, 2015

- 1
2
3 12. Rizzuto I, Behrens RF, Smith LA: Risk of ovarian cancer in women treated with ovarian
4
5 stimulating drugs for infertility. *Cochrane Database Syst Rev* 8:CD008215, 2013
6
- 7 13. Reigstad MM, Larsen IK, Myklebust TA, et al: Risk of breast cancer following fertility
8
9 treatment--a registry based cohort study of parous women in Norway. *Int J Cancer*
10
11 136:1140-8, 2015
12
- 13 14. van Leeuwen FE, Klip H, Mooij TM, et al: Risk of borderline and invasive ovarian
14
15 tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. *Hum*
16
17 *Reprod* 26:3456-65, 2011
18
- 19 15. Stewart LM, Holman CD, Finn JC, et al: In vitro fertilization is associated with an
20
21 increased risk of borderline ovarian tumours. *Gynecol Oncol* 129:372-6, 2013
22
23
- 24 16. Stewart LM, Holman CD, Aboagye-Sarfo P, et al: In vitro fertilization, endometriosis,
25
26 nulliparity and ovarian cancer risk. *Gynecol Oncol* 128:260-4, 2013
27
28
- 29 17. Siristatidis C, Sergentanis TN, Kanavidis P, et al: Controlled ovarian hyperstimulation
30
31 for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-
32
33 analysis. *Hum Reprod Update* 19:105-23, 2013
34
35
- 36 18. Zegers-Hochschild F, Adamson GD, de Mouzon J, et al: The International Committee
37
38 for Monitoring Assisted Reproductive Technology (ICMART) and the World Health
39
40 Organization (WHO) Revised Glossary on ART Terminology, 2009. *Hum Reprod* 24:2683-7,
41
42 2009
43
44
- 45 19. Information Services Division: Scottish Cancer Registry, NHS National Services
46
47 Scotland, 2010. [http://www.isdscotland.org/Health-Topics/Cancer/Scottish-Cancer-](http://www.isdscotland.org/Health-Topics/Cancer/Scottish-Cancer-Registry.asp)
48
49 [Registry.asp](http://www.isdscotland.org/Health-Topics/Cancer/Scottish-Cancer-Registry.asp)
50
51
- 52 20. Office for National Statistics: Cancer Registrations, 1971 to 2011, Cancer Statistics
53
54 Registrations, Office for National Statistics, 2014;
55
56
57
58
59
60

1
2
3 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2014-06-19#tab-Cancer-registrations--1971-to-2011>

4
5
6
7
8
9
10 21. Parkin DM CV, Ferlay J, Galceran J, Storm HH, Whelan SL: Comparability and Quality
11 Control in Cancer Registration, IARC technical Reports. Lyon, International Agency for
12 Research on Cancer, 1994.

13
14
15
16
17 22. Breslow NE, Day NE: Statistical Methods in Cancer Research. Lyon, France,
18 International Agency for Research on Cancer, 1987.

19
20
21 23. Stata Corp: Stata Statistical Software: Release 12. College Station Tx, Stata Corp LP,
22 2013.

23
24
25
26 24. Adamson GD, Tabangin M, Macaluso M, et al: The Number of Babies Born Globally
27 after Treatment with the Assisted Reproductive Technologies (Art). Fertility and Sterility
28 100:S42-S42, 2013.

29
30
31
32 25. Stewart LM, Holman CD, Hart R, et al: In vitro fertilization and breast cancer: is there
33 cause for concern? Fertil Steril 98:334-40, 2012.

34
35
36
37 26. Domar AD, Conboy L, Denardo-Roney J, et al: Lifestyle behaviors in women
38 undergoing in vitro fertilization: a prospective study. Fertil Steril 97:697-701 e1, 2012

39
40
41
42 27. Key TJ, Verkasalo PK, Banks E: Epidemiology of breast cancer. Lancet Oncol 2:133-40,
43 2001

44
45
46
47 28. Cetin I, Cozzi V, Antonazzo P: Infertility as a cancer risk factor - a review. Placenta 29
48 Suppl B:169-77, 2008

49
50
51 29. Barry JA, Azizia MM, Hardiman PJ: Risk of endometrial, ovarian and breast cancer in
52 women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum
53 Reprod Update 20:748-58, 2014

- 1
2
3 30. Wentzensen N, Poole EM, Trabert B, et al: Ovarian Cancer Risk Factors by Histologic
4
5 Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol 34:2888-98,
6
7 2016
8
9
10 31. Ovarian Cancer Research Fund Alliance (OCRFA): Ovarian Cancer Statistics.
11
12 <http://www.ovariancancer.org/about/statistics/>, 2016
13
14 32. Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal
15
16 and ultrasound screening for ovarian cancer, and stage distribution of detected cancers:
17
18 results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening
19
20 (UKCTOCS). Lancet Oncol 10:327-40, 2009
21
22
23 33. Jones ME, Swerdlow AJ: Bias in the standardized mortality ratio when using general
24
25 population rates to estimate expected number of deaths. Am J Epidemiol 148:1012-7, 1998
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60